CI

At a glance

ClinicalIndex Comparison Record
Phase 4Completed· 34 enrolled
Drug / intervention
Olux-E Foam +1 moredrug
Likely dose
Clobetasol propionate 0.05% foam or lotion applied twice dailyAI-extracted
Key inclusion· 5
  • ✓Body surface area affected with psoriasis between 4% and 20%
  • ✓Target lesion of at least 2 cm² on elbow and/or knee with Psoriasis Grading Scale score of 2 or 3
  • ✓Elbow and/or knee plaque-type psoriasis with mild or moderate Psoriasis Global Assessment (score 2 or 3)
  • ✓Definitive diagnosis of elbow and/or knee plaque-type psoriasis
Key exclusion· 5
  • ✕Use of any emollient applied to psoriasis plaques being treated with study medication during the study
  • ✕Other serious skin disorder or any chronic medical condition that is not well controlled
  • ✕Pregnancy, attempting to become pregnant, or lactating
  • ✕Any major illness within 30 days prior to baseline visit

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00852761
NCT00852761Phase 4Completed
CompareCT.gov

A Study to Evaluate Safety and Efficacy of Clobetasol Propionate for Treatment of Plaque-Type Psoriasis in Adult Subjects.

Stiefel, a GSK Company·interventional·Posted Feb 27, 2009·Updated Apr 23, 2012

In Brief

A Phase 4 clinical trial evaluating Olux-E Foam and Clobex lotion for Plaque-Type Psoriasis. Completed, enrolled 34 participants across 1 site.

Detailed Summary

The purpose of the study is to determine the efficacy and safety of two different forms of a topical steroid (clobetasol propionate) in patients with plaque-type psoriasis.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsPlaque-Type Psoriasis
CountriesUnited States
CollaboratorsGlaxoSmithKline

Timeline

Phase 4CompletedFinished
200920102011201220132014201520162017201820192020202120222023202420252026
First PostedFeb 27, 2009
Enrollment StartMar 1, 2009
Primary CompletionJun 1, 2009
Study CompletionAug 1, 2009
TodayJul 2, 2026
Enrollment to primary: 3 monthsPosted 17.3 years ago

Interventions

Olux-E Foamdrug

Olux-E (clobetasol propionate 0.05%) foam. Starting at baseline, subjects were to apply twice daily Olux-E foam to the affected elbows and/or knees up to day 15.

Clobex lotiondrug

Clobetasol propionate 0.05% lotion. Starting at baseline, subjects were to apply twice daily Clobex lotion to the affected elbows and/or knees up to day 15